H.C. Wainwright raised the firm’s price target on Bionano Genomics (BNGO) to $11 from $10 and keeps a Buy rating on the shares. The company demonstrated sequential revenue growth in Q2, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics Reports Q2 2025 Financial Results
- Bionano Genomics Reported Earnings. Did it Beat Estimates?
- BioNano Genomics: Strategic Innovations and OGM Validation Drive Buy Rating
- Bionano Genomics publication shows utility of optical genome mapping in T-ALL
- Bionano Genomics announces release of latest versions of its VIA, Solve